Trial NCT05011526
Publication Torales J, Vaccine, 2022
Primary outcome on the report: 1) Immediate adverse events, solicited local and systemic adverse events (evaluated up to 7 days after each dose of the study intervention), and unsolicited adverse events (assessed up to 28 days after each dose of the study intervention);
2) Wild-type anti-SARS-CoV-2 virus-neutralizing antibody GMTs, GMT ratio between MVC-COV1901 and AZD1222, geometric mean fold rise (GMFR) from baseline antibody levels, and seroconversion rates (SCR) at day 14 after the second dose of the vaccine.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.